Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE6.8700
- TODAY'S CHANGE (%)-0.1250 (-1.7870%)
- Bid / Lots6.8600/ 2
- Ask / Lots6.9000/ 5
- Open / Previous Close6.9600 / 6.9950
- Day Range
- 52 Week Range
- Volume99,831
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 451 | 6.96 |
| 09:34 ET | 100 | 6.9786 |
| 09:36 ET | 100 | 6.99 |
| 09:38 ET | 3944 | 6.905 |
| 09:41 ET | 1184 | 6.95 |
| 09:43 ET | 3000 | 6.875 |
| 09:48 ET | 1000 | 6.95 |
| 09:50 ET | 500 | 6.9374 |
| 09:52 ET | 100 | 6.95 |
| 10:01 ET | 400 | 6.9098 |
| 10:03 ET | 350 | 6.9825 |
| 10:06 ET | 500 | 6.95 |
| 10:08 ET | 144 | 6.95 |
| 10:10 ET | 288 | 6.95 |
| 10:12 ET | 290 | 6.9 |
| 10:14 ET | 149 | 6.955 |
| 10:15 ET | 148 | 6.955 |
| 10:19 ET | 100 | 6.92 |
| 10:26 ET | 648 | 6.98 |
| 10:30 ET | 2753 | 6.95 |
| 10:32 ET | 718 | 6.994 |
| 10:33 ET | 100 | 7.01 |
| 10:37 ET | 100 | 6.971624 |
| 10:46 ET | 100 | 7 |
| 10:48 ET | 1181 | 7.01 |
| 10:50 ET | 1000 | 7.034133 |
| 10:57 ET | 100 | 7.03 |
| 11:00 ET | 158 | 7.05 |
| 11:04 ET | 146 | 7.05 |
| 11:13 ET | 121 | 7.05 |
| 11:18 ET | 150 | 7.0899 |
| 11:24 ET | 305 | 7.01 |
| 11:31 ET | 200 | 6.995 |
| 11:40 ET | 922 | 6.99 |
| 11:42 ET | 240 | 6.995 |
| 11:45 ET | 180 | 6.96 |
| 11:47 ET | 700 | 6.995 |
| 11:49 ET | 1140 | 6.94 |
| 11:51 ET | 200 | 6.91 |
| 11:54 ET | 1445 | 6.87 |
| 11:56 ET | 3890 | 6.87 |
| 11:58 ET | 1201 | 6.93 |
| 12:00 ET | 120 | 6.93 |
| 12:02 ET | 2160 | 6.9001 |
| 12:05 ET | 360 | 6.9 |
| 12:07 ET | 1100 | 6.935 |
| 12:09 ET | 1600 | 6.955 |
| 12:12 ET | 1100 | 6.95 |
| 12:14 ET | 453 | 6.955 |
| 12:18 ET | 300 | 6.945 |
| 12:20 ET | 750 | 6.94 |
| 12:21 ET | 504 | 6.95 |
| 12:25 ET | 200 | 6.945 |
| 12:27 ET | 546 | 6.955 |
| 12:30 ET | 740 | 6.96 |
| 12:32 ET | 1419 | 6.95 |
| 12:34 ET | 348 | 6.939 |
| 12:38 ET | 4440 | 6.95 |
| 12:41 ET | 209 | 6.9 |
| 12:43 ET | 2444 | 6.95 |
| 12:45 ET | 400 | 6.93 |
| 12:52 ET | 460 | 6.91 |
| 12:54 ET | 100 | 6.9 |
| 12:56 ET | 388 | 6.91 |
| 12:57 ET | 100 | 6.91 |
| 12:59 ET | 200 | 6.9 |
| 01:01 ET | 812 | 6.9 |
| 01:10 ET | 100 | 6.88 |
| 01:14 ET | 1563 | 6.894 |
| 01:15 ET | 300 | 6.91 |
| 01:17 ET | 100 | 6.92 |
| 01:19 ET | 200 | 6.91 |
| 01:21 ET | 300 | 6.915 |
| 01:24 ET | 1340 | 6.9 |
| 01:28 ET | 2182 | 6.87 |
| 01:30 ET | 225 | 6.87 |
| 01:32 ET | 4574 | 6.8401 |
| 01:33 ET | 100 | 6.85 |
| 01:35 ET | 200 | 6.84 |
| 01:39 ET | 300 | 6.85 |
| 01:42 ET | 1300 | 6.9 |
| 01:44 ET | 5350 | 6.89 |
| 01:46 ET | 1975 | 6.889 |
| 01:53 ET | 1823 | 6.91 |
| 01:57 ET | 200 | 6.9 |
| 02:06 ET | 569 | 6.9 |
| 02:13 ET | 1374 | 6.96 |
| 02:18 ET | 338 | 6.905 |
| 02:22 ET | 4662 | 6.9 |
| 02:27 ET | 100 | 6.87 |
Sep 4, 2024
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors, from 8:01AM ET on Wednesday Sep 04, 2024 by Dow Jones
8:01AM ET on Wednesday Sep 04, 2024 by Dow Jones
Sep 3, 2024
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference, from 8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 224.4M | -4.0x | --- |
XBiotech Inc | 225.4M | -6.6x | --- |
Trevi Therapeutics Inc | 225.8M | -8.4x | --- |
Cabaletta Bio Inc | 226.7M | -2.4x | --- |
Omeros Corp | 221.4M | -1.2x | --- |
Corbus Pharmaceuticals Holdings Inc | 231.6M | -3.5x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $224.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
